Plus TherapeuticsPSTV
PSTV
About: Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
Employees: 21
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
600% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 1
60% more funds holding
Funds holding: 10 [Q4 2024] → 16 (+6) [Q1 2025]
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
8.19% less ownership
Funds ownership: 11.49% [Q4 2024] → 3.3% (-8.19%) [Q1 2025]
53% less capital invested
Capital invested by funds: $780K [Q4 2024] → $369K (-$411K) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5.50
1,652%
upside
Avg. target
$13
4,040%
upside
High target
$21
6,429%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Ascendiant Capital Edward Woo | 6,429%upside $21 | Buy Maintained | 5 Jun 2025 |
HC Wainwright & Co. Sean Lee | 1,652%upside $5.50 | Buy Maintained | 28 Mar 2025 |
Financial journalist opinion
Based on 3 articles about PSTV published over the past 30 days
Negative
Zacks Investment Research
2 weeks ago
Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates
Plus Therapeutics (PSTV) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.75 per share a year ago.
Neutral
GlobeNewsWire
2 weeks ago
Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights
Company continues to progress both REYOBIQ™ radiotherapeutic clinical trials and CNSide® CSF assay platform launch readiness HOUSTON, May 30, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the first quarter ended March 31, 2025, and provides an overview of recent and upcoming business highlights. “We improved our cash position in the first quarter as a result of both a financing and grant support,” said Marc H.
Neutral
GlobeNewsWire
3 weeks ago
Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q
HOUSTON, May 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced it received a delinquency notification letter from Nasdaq on May 21, 2025, which indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the delayed filing of the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2025 (the “Quarterly Report”). The Nasdaq Listing Rule requires listed companies to timely file all required periodic financial reports with the U.S. Securities and Exchange Commission (the “SEC”).
Negative
Zacks Investment Research
1 month ago
Plus Therapeutics (PSTV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Plus (PSTV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
GlobeNewsWire
1 month ago
Plus Therapeutics' REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)
Multiple long-term LM survivors in those patients receiving multiple doses of REYOBIQ RNA sequencing data show early tumor apoptosis and activation of innate immune responses Updated ReSPECT data presented at the 2025 Nuclear Medicine and Neurooncology Conference HOUSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the presentation of new data on its lead drug REYOBIQ™ (rhenium Re186 obisbemeda) during both an oral presentation and a poster presented at the Nuclear Medicine and Neurooncology Conference. The meeting was held May 9-10, 2025 in Vienna, Austria.
Neutral
GlobeNewsWire
1 month ago
Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference
HOUSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces that it will participate in the D. Boral Capital Inaugural Global Conference.
Positive
Zacks Investment Research
1 month ago
5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms
Innovation is at its peak for the Zacks Medical-Drugs industry. AUPH, HRTX, ESPR, PYXS and PSTV may prove to be good additions to one's portfolio.
Neutral
GlobeNewsWire
1 month ago
Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors
HOUSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the appointment of Kyle Guse, J.D., M.B.A. to the Company's Board of Directors where he will serve as chair of the Audit Committee and on the Compensation Committee.
Neutral
GlobeNewsWire
2 months ago
Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases
New abstract published ahead of the Nuclear Medicine and Neurooncology Conference shows promise for REYOBIQ New abstract published ahead of the Nuclear Medicine and Neurooncology Conference shows promise for REYOBIQ
Positive
Zacks Investment Research
2 months ago
Plus (PSTV) Upgraded to Buy: Here's What You Should Know
Plus (PSTV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Charts implemented using Lightweight Charts™